Periodontal Therapeutics Market - Snapshot

Periodontal therapeutics are products used in the treatment of periodontal diseases. These products include systemic antibiotics such as doxycycline, minocycline, metronidazole, and amoxicillin and locally applied antibiotics such as Arestin, Atridox, and PerioChip. These antibiotics can either be administered to patients orally or delivered directly to dental pockets, without systemic doses. The global periodontal market was valued at around US$ 500 Mn in 2017 and is anticipated to expand at a CAGR of more than 9.0% from 2018 to 2026 to reach around US$ 1100 Mn by 2026. Increase in prevalence of periodontal diseases observed across the globe is likely to fuel the global periodontal therapeutics market from 2018 to 2026.

Rise in the global burden of periodontal diseases is a major factor driving the periodontal therapeutics market. Periodontal diseases, including periodontitis and gingivitis, are prevalent in developing and developed countries and affect around 20% to 50% of the global population. According to the Global Burden of Disease Study conducted over a time span of 20 years, severe periodontitis is one of the most prevalent diseases across the globe. It has prevalence of around 11.2% and approximately 743 million people are affected by it worldwide. The overall burden of periodontal diseases worldwide has increased by nearly 57.3% from 1990 to 2010. Periodontitis a major cause of tooth loss among the adult population across the world. Individuals are at major risk of acquiring edentulism, masticatory dysfunction, and multiple tooth loss. This, in turn, affects nutrition, self-esteem, quality of life, and imposes high health care and significant socio-economic costs.

global-periodontal-therapeutics-market.jpg

Increase in number of diabetic patients across the globe is also contributing to the expansion of the market. According to the American Academy of Periodontology, individuals with diabetes are more susceptible to have periodontal diseases, due to the fact that individuals having diabetes are more likely to contract infections. Periodontal diseases are considered a complication of diabetes. Diabetic patients with periodontal diseases have difficulty in controlling their blood sugar and are also at a risk of diabetes-related complications. According to the World Health Organization estimates, globally, the number of individuals with diabetes has increased from 108 million in 1980 to 422 million in 2014. Rise in global burden of diabetes is expected to increase the number of individuals with periodontal diseases in the next few years.

Rise in global geriatric population is also projected to increase the number of patients with periodontal diseases. According to the United Nations’ World Population Ageing report, globally, there were 962 million people above the age of 60 years in 2017, which is expected to rise two-fold and reach 2.1 billion by 2050. The number of geriatric people are expected to outnumber children under the age of 10 (1.41 billion versus 1.35 billion) by 2030. The geriatric population aged 60 years and above is estimated to be more than the combined population of adolescents and youth in the age group 10–24 years by 2050. Rise in geriatric population with increased tooth retention also raises the chances of developing periodontitis, as the prevalence of periodontitis rises with age and the incidence increases steeply among this population. Surge in geriatric population is expected to drive the overall burden of periodontitis. This, in turn, is projected boost demand for therapies and products used to manage the disease.

The periodontal therapeutics market is segregated based on product type, distribution channel, and region. In terms of product type, the local antibiotics segment is estimated to account for a large share of the market. Based on distribution channels, the hospital pharmacies segment constituted for a major share of the market in 2017. The segment is likely to expand at a considerable growth rate as compared to other distribution channels during the forecast period.

North America is projected to be a major market in terms of revenue during the forecast period. Initiatives by local governments to improve oral care, especially for individuals suffering from untreated dental diseases, and provision of experienced dental workforce to address the large unmet needs are expected to drive the market in the region. These measures are expected to help the region maintain its dominance during the forecast period. However, the market in Asia Pacific is likely to expand at a considerable growth rate during the forecast period, due to exponential rise in the geriatric population and increase in awareness among consumers regarding dental health.

Prominent players in the global periodontal therapeutics market include Den-Mat Holdings, LLC, Valeant Pharmaceuticals International, Inc., Dexcel Pharma, 3M Company, Oral Science, and Kaken Pharmaceutical Co., Ltd. Surge in awareness about oral health primarily due to national and community policies regarding effective control on diet and nutrition risk factors for oral diseases such as periodontal and dental disease and development of novel products for the treatment of periodontal diseases are expected to provide fillip for antibiotic based treatment options. Companies can also focus on introducing locally applied antibiotics in countries with sizeable population affected with periodontal diseases in order to capitalize on the large unmet needs in these countries.

Periodontal Therapeutics Market – Overview

Periodontal therapeutics are effective adjunctive therapies used in the treatment of periodontal pathogens. These therapies include systemic antibiotics, such as doxycycline, minocycline, metronidazole, and other antibiotics comprising amoxicillin, azithromycin, etc. and local antibiotics, including Arestin, Atridox, PerioChip, and others. This report analyzes the current and future prospects of the periodontal therapeutics market based on product type, distribution channel, and geography.

This study is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the periodontal therapeutics market in the near future. Primary research formed the bulk of our research efforts, with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation, and various international and national databases. The report provides estimated market size in terms of US$ Mn (US$ in million) for product type, distribution channel, and geography for the period of 2018 to 2026.

The report contains an elaborative executive summary, which includes market snapshot providing information on various segments of the market. It also provides information and data analysis of the market with respect to market segments based on product type, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that can influence the periodontal therapeutics market in the current and future scenario. The report also provides Porter’s five force analysis that studies five factors and their impact on the periodontal therapeutics market.

Market share of key players is analyzed to signify the contribution of these players toward the revenue of the market. As such, these factors are likely to help market players in deciding about business strategies and plans for strengthening their position in the global market. Based on geography, the market has been analyzed for five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The study also covers detailed country analysis in these regions for the periodontal therapeutics market.

The report also profiles major players in the periodontal therapeutics market and provides their key attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report include Den-Mat Holdings, LLC, Valeant Pharmaceuticals International, Inc., Dexcel Pharma, 3M Company, and Kaken Pharmaceutical Co., Ltd. Inorganic growth measurements and business collaborations were the primary strategies adopted by the major market players to cement their position in the periodontal therapeutics market.

The periodontal therapeutics market has been segmented as follows:

  • Periodontal Therapeutics Market, by Product Type, Revenue (US$ Mn) 2018-2026
    • Systemic Antibiotics
      • Doxycycline
      • Minocycline
      • Metronidazole
      • Others
    • Local Antibiotics
      • Arestin
      • Atridox
      • PerioChip
      • Others
  • Periodontal Therapeutics Market, by Distribution Channel, Revenue (US$ Mn) 2018-2026
    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Stores
    • E-commerce
  • Periodontal Therapeutics Market, by Geography, Revenue (US$ Mn), 2018-2026
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • GCC Countries
      • Israel
      • Rest of Middle East & Africa
.